Lisata Therapeutics
| Company type | Public |
|---|---|
| Nasdaq: LSTA | |
| Industry | Biopharmaceuticals |
| Headquarters | Basking Ridge, New Jersey, United States |
Key people | David J. Mazzo (CEO) |
| Website | lisata |
Lisata Therapeutics is an American clinical stage pharmaceutical company active in the field of oncology, specifically aimed at developing and commercializing new cancer therapies. It was formed through the acquisition of Cend Therapeutics by Caladrius Biosciences in September 2022.[1]
In April 2024 the FDA granted their product, certepetide, orphan drug status.[2] Non-clinical data collected by Lisata and others have demonstrated enhanced delivery of various existing and emerging anti-cancer therapies, including chemotherapies, immunotherapies and RNA-based therapeutics when used with certepetide.[3]
References
[edit]- ^ Caladrius Biosciences and Cend Therapeutics Announce Closing of Merger and the Emergence of Lisata Therapeutics, September 15, 2022
- ^ Barrie, Robert (April 10, 2024). "Lisata wins FDA orphan drug status for bone cancer candidate". Pharmaceutical Technology. Verdict Media Limited. Retrieved 5 November 2024.
- ^ "Certepetide (Synonyms: CEND-1; iRGD; LSTA1)". MedChemExpress. MedChemExpress. Retrieved 5 November 2024.
